A first-in-human study of the anti-LAG-3 mAb favezelimab plus pembrolizumab in previously treated, advanced microsatellite-stable colorectal cancer showed promising antitumor activity, particularly in participants with PD-L1 CPS ≥ 1 tumors51. Here, CD274 is linked to colorectal cancer.